Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a sell rating to a hold rating in a report published on Wednesday morning.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

NH has been the subject of a number of other research reports. BidaskClub upgraded shares of NantHealth from a hold rating to a buy rating in a research note on Friday, July 6th. Canaccord Genuity restated a hold rating on shares of NantHealth in a research note on Tuesday, July 3rd. Finally, ValuEngine upgraded shares of NantHealth from a hold rating to a buy rating in a research note on Monday, July 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. NantHealth has a consensus rating of Hold and an average price target of $4.31.

NH traded up $0.05 during midday trading on Wednesday, reaching $1.37. 84,121 shares of the company’s stock were exchanged, compared to its average volume of 138,819. The stock has a market cap of $144.50 million, a price-to-earnings ratio of -1.22 and a beta of -0.04. The company has a quick ratio of 1.48, a current ratio of 1.50 and a debt-to-equity ratio of 1.34. NantHealth has a one year low of $1.24 and a one year high of $4.05.

NantHealth (NASDAQ:NH) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $22.05 million during the quarter, compared to analysts’ expectations of $24.50 million. NantHealth had a negative net margin of 124.02% and a negative return on equity of 49.56%. Equities research analysts expect that NantHealth will post -0.7 EPS for the current fiscal year.

A hedge fund recently raised its stake in NantHealth stock. Dimensional Fund Advisors LP increased its stake in NantHealth Inc (NASDAQ:NH) by 41.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,348 shares of the company’s stock after purchasing an additional 35,445 shares during the period. Dimensional Fund Advisors LP owned 0.11% of NantHealth worth $398,000 as of its most recent SEC filing. Institutional investors own 5.63% of the company’s stock.

About NantHealth

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

Recommended Story: Penny Stocks

Get a free copy of the Zacks research report on NantHealth (NH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with's FREE daily email newsletter.